TICKERNERD
Menu
BMEABMEAHealthcare · Biotechnology

BMEA Stock Forecast: Biomea Fusion, Inc. Price Predictions for 2026-2027

Last close, 12 Aug 2026
$1.28
−0.78% on the day

The 7 Wall Street analysts covering Biomea Fusion, Inc. hold a median 12-month price target of $7 — +446.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 44 of 100 as at 12 Aug 2026 — in the lower half.

Market cap
$93.3M
Ticker Nerd rank
44 / 100
Median analyst target
$7.00
Analysts covering
7
Total return, dividends reinvested
1W
+1.6%
1M
−3.0%
YTD
+3.2%
1Y
−22.4%
From 52W high
−52.1%
From 52W low
+33.8%
$0.96
$2.67
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BMEA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Biomea Fusion, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Aug 2026
44 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
85
Size
76
Issuance
67
Revisions
58
Accruals
54
Volatility
26
Momentum
25
Value
23
Quality
18

Growth (85): Sales and profits are climbing, and climbing faster than before.

Quality (18): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BMEA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BMEA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00Oct 25Jan 26Apr 26Jul 26BMEAHigh $9.00Median $7.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says7 analysts
6 Buy0 Hold1 Sell
Low $4.00Median $7.00High $9.00

The green dot is the last close — the median target sits +446.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
5 May 2026CitizensInitiatesMarket Outperform$9.00
28 Apr 2026D. Boral CapitalMaintainsBuy$12
8 Apr 2026D. Boral CapitalMaintainsBuy—
27 Mar 2026CitigroupMaintainsBuy—
25 Mar 2026D. Boral CapitalMaintainsBuy—
13 Jan 2026D. Boral CapitalMaintainsBuy—
10 Nov 2025CitigroupMaintainsBuy—
5 Nov 2025D. Boral CapitalMaintainsBuy—
27 Oct 2025D. Boral CapitalMaintainsBuy—
7 Oct 2025D. Boral CapitalMaintainsBuy—
3 Oct 2025D. Boral CapitalMaintainsBuy—
28 Aug 2025JefferiesInitiatesBuy—
11 Aug 2025CitigroupMaintainsBuy—
6 Aug 2025D. Boral CapitalMaintainsBuy—
6 Aug 2025ScotiabankMaintainsSector Outperform—
21 July 2025D. Boral CapitalMaintainsBuy—
16 July 2025CitigroupMaintainsBuy—
24 June 2025D. Boral CapitalMaintainsBuy—
18 June 2025D. Boral CapitalMaintainsBuy—
13 June 2025D. Boral CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BMEA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

BMEA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Biomea Fusion, Inc. (BMEA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.1×

Cheaper than 82% of US stocks

Price / sales
—
Price / book
3.2×

Cheaper than 34% of US stocks

EV / EBITDA
−1.1×

Cheaper than 68% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 33% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−164.1%

Higher than 8% of US stocks

Return on assets
−63.5%

Higher than 6% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

BMEA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
BMEABiomea Fusion, Inc.$93.3M
44
FBIOFortress Biotech, Inc.$91.4M
92
GANXGain Therapeutics, Inc.$89.6M
29
ALDXAldeyra Therapeutics, Inc.$91.7M
50
PYPDPolyPid Ltd.$92.4M
52
RLYBRallybio Corp.$87.6M
54
VRCAVerrica Pharmaceuticals, Inc.$87.4M
76

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Biomea Fusion, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BMEA news & analysis

Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity

GlobeNewsWire · 13 Aug 2026positive

Biomea Fusion announced that the first patient has been dosed in its OPAL study, which evaluates icovamenib in combination with low-dose semaglutide for obesity. The study is designed to assess the combination's potential impact on physical function, body weight, body composition, muscle health, and metabolic outcomes.

Why it matters — This milestone marks advancement of Biomea Fusion's pipeline into the obesity space, expanding the potential applications of its lead candidate icovamenib beyond its existing focus.

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

GlobeNewsWire · 5 Aug 2026neutral

Biomea Fusion, a clinical-stage diabetes and obesity company, reported its financial results for the second quarter ended June 30, 2026, and provided a business update on August 5, 2026.

Why it matters — This announcement provides BMEA watchers with the company's quarterly financial results and current business status via its official update.

FAQ

Frequently asked questions about BMEA stock

What is the BMEA stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Biomea Fusion, Inc. have a median 12-month price target of $7, with estimates ranging from $4 to $9. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BMEA stock a buy right now?

Of the 7 analysts covering Biomea Fusion, Inc., 6 rate it a Buy, 0 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Biomea Fusion, Inc. 44 out of 100 across roughly 4,600 US stocks as at 12 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BMEA?

As at 12 Aug 2026, Biomea Fusion, Inc. ranks 44 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (85 of 100).

Will BMEA stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +446.9% from the last close, and Ticker Nerd's factor model ranks Biomea Fusion, Inc. 44 out of 100 as at 12 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BMEA stock forecast for 2030?

No analyst covering Biomea Fusion, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BMEA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $9 over the next 12 months.

How has BMEA stock performed over the past year?

Biomea Fusion, Inc. returned -22.4% over the 12 months to 12 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Biomea Fusion, Inc. do?

Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of oral covalent small-molecule drugs for treating metabolic diseases, with a primary focus on diabetes and obesity.

What is the latest news on BMEA?

The most recent item we track (GlobeNewsWire, 13 Aug 2026): "Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity". Biomea Fusion announced that the first patient has been dosed in its OPAL study, which evaluates icovamenib in combination with low-dose semaglutide for obesity. The study is designed to assess the combination's potential impact on physical function, body weight, body composition, muscle health, and metabolic outcomes.

Company

About Biomea Fusion, Inc.

Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of oral covalent small-molecule drugs for treating metabolic diseases, with a primary focus on diabetes and obesity. Its lead product candidate, icovamenib, is an orally bioavailable, potent, and selective covalent inhibitor of menin, a scaffold protein involved in histone modification and epigenetic gene regulation that influences cell cycle control, apoptosis, and DNA damage repair. Icovamenib is being evaluated in clinical studies such as COVALENT-111 and COVALENT-121 for type 2 diabetes, demonstrating potential in glycemic control and benefits for insulin-deficient patient populations. The company is also advancing BMF-650, a next-generation oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist, which shows promise in preclinical models for weight loss, appetite suppression, and glycemic improvement in obesity and related disorders. Biomea Fusion employs its proprietary FUSION System discovery platform to build a pipeline targeting these high-need areas in the metabolic disease landscape. Founded in 2017 and headquartered in San Carlos, California, the company operates exclusively in the biopharmaceutical sector, emphasizing innovative oral therapies to address unmet needs in diabetes and obesity management.

CEO Dr. Michael J. M. Hitchcock Ph.D. · 37 employees · United States · https://biomeafusion.com